Cargando…
Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment
BACKGROUND: In recent years, immunotherapies and targeted therapies contribute to population-level improvement in NSCLC cancer-specific survival, however, the two novel therapeutic options have mainly benefit patients containing mutated driven genes. Thus, to explore other potential genes related wi...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686609/ https://www.ncbi.nlm.nih.gov/pubmed/34923982 http://dx.doi.org/10.1186/s12890-021-01796-w |
_version_ | 1784618050471854080 |
---|---|
author | Song, Liyuan Wang, Xianhui Cheng, Wang Wu, Yi Liu, Min Liu, Ruizi Zhang, Shenyi Xia, Hong Liu, Hao Tai, Xuejiao Zhao, Huzi Li, Xihua Ji, Fuyun |
author_facet | Song, Liyuan Wang, Xianhui Cheng, Wang Wu, Yi Liu, Min Liu, Ruizi Zhang, Shenyi Xia, Hong Liu, Hao Tai, Xuejiao Zhao, Huzi Li, Xihua Ji, Fuyun |
author_sort | Song, Liyuan |
collection | PubMed |
description | BACKGROUND: In recent years, immunotherapies and targeted therapies contribute to population-level improvement in NSCLC cancer-specific survival, however, the two novel therapeutic options have mainly benefit patients containing mutated driven genes. Thus, to explore other potential genes related with immunity or targeted therapies may provide novel options to improve survival of lung cancer patients without mutated driven genes. CTSF is unique in human cysteine proteinases. Presently, CTSF has been detected in several cell lines of lung cancer, but its role in progression and prognosis of lung cancer remains unclear. METHODS: CTSF expression and clinical datasets of lung cancer patients were obtained from GTEx, TIMER, CCLE, THPA, and TCGA, respectively. Association of CTSF expression with clinicopathological parameters and prognosis of lung cancer patients was analyzed using UALCAN and Kaplan–Meier Plotter, respectively. LinkedOmics were used to analyze correlation between CTSF and CTSF co-expressed genes. Protein–protein interaction and gene–gene interaction were analyzed using STRING and GeneMANIA, respectively. Association of CTSF with molecular markers of immune cells and immunomodulators was analyzed with Immunedeconv and TISIDB, respectively. RESULTS: CTSF expression was currently only available for patients with NSCLC. Compared to normal tissues, CTSF was downregulated in NSCLC samples and high expressed CTSF was correlated with favorable prognosis of NSCLC. Additionally, CTSF expression was correlated with that of immune cell molecular markers and immunomodulators both in LUAD and LUSC. Noticeably, high expression of CTSF-related CTLA-4 was found to be associated with better OS of LUAD patients. Increased expression of CTSF-related LAG-3 was related with poor prognosis of LUAD patients while there was no association between CTSF-related PD-1/PD-L1 and prognosis of LUAD patients. Moreover, increased expression of CTSF-related CD27 was related with poor prognosis of LUAD patients while favorable prognosis of LUSC patients. CONCLUSIONS: CTSF might play an anti-tumor effect via regulating immune response of NSCLC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-021-01796-w. |
format | Online Article Text |
id | pubmed-8686609 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-86866092021-12-20 Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment Song, Liyuan Wang, Xianhui Cheng, Wang Wu, Yi Liu, Min Liu, Ruizi Zhang, Shenyi Xia, Hong Liu, Hao Tai, Xuejiao Zhao, Huzi Li, Xihua Ji, Fuyun BMC Pulm Med Research BACKGROUND: In recent years, immunotherapies and targeted therapies contribute to population-level improvement in NSCLC cancer-specific survival, however, the two novel therapeutic options have mainly benefit patients containing mutated driven genes. Thus, to explore other potential genes related with immunity or targeted therapies may provide novel options to improve survival of lung cancer patients without mutated driven genes. CTSF is unique in human cysteine proteinases. Presently, CTSF has been detected in several cell lines of lung cancer, but its role in progression and prognosis of lung cancer remains unclear. METHODS: CTSF expression and clinical datasets of lung cancer patients were obtained from GTEx, TIMER, CCLE, THPA, and TCGA, respectively. Association of CTSF expression with clinicopathological parameters and prognosis of lung cancer patients was analyzed using UALCAN and Kaplan–Meier Plotter, respectively. LinkedOmics were used to analyze correlation between CTSF and CTSF co-expressed genes. Protein–protein interaction and gene–gene interaction were analyzed using STRING and GeneMANIA, respectively. Association of CTSF with molecular markers of immune cells and immunomodulators was analyzed with Immunedeconv and TISIDB, respectively. RESULTS: CTSF expression was currently only available for patients with NSCLC. Compared to normal tissues, CTSF was downregulated in NSCLC samples and high expressed CTSF was correlated with favorable prognosis of NSCLC. Additionally, CTSF expression was correlated with that of immune cell molecular markers and immunomodulators both in LUAD and LUSC. Noticeably, high expression of CTSF-related CTLA-4 was found to be associated with better OS of LUAD patients. Increased expression of CTSF-related LAG-3 was related with poor prognosis of LUAD patients while there was no association between CTSF-related PD-1/PD-L1 and prognosis of LUAD patients. Moreover, increased expression of CTSF-related CD27 was related with poor prognosis of LUAD patients while favorable prognosis of LUSC patients. CONCLUSIONS: CTSF might play an anti-tumor effect via regulating immune response of NSCLC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-021-01796-w. BioMed Central 2021-12-20 /pmc/articles/PMC8686609/ /pubmed/34923982 http://dx.doi.org/10.1186/s12890-021-01796-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Song, Liyuan Wang, Xianhui Cheng, Wang Wu, Yi Liu, Min Liu, Ruizi Zhang, Shenyi Xia, Hong Liu, Hao Tai, Xuejiao Zhao, Huzi Li, Xihua Ji, Fuyun Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment |
title | Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment |
title_full | Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment |
title_fullStr | Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment |
title_full_unstemmed | Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment |
title_short | Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment |
title_sort | expression signature, prognosis value and immune characteristics of cathepsin f in non-small cell lung cancer identified by bioinformatics assessment |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686609/ https://www.ncbi.nlm.nih.gov/pubmed/34923982 http://dx.doi.org/10.1186/s12890-021-01796-w |
work_keys_str_mv | AT songliyuan expressionsignatureprognosisvalueandimmunecharacteristicsofcathepsinfinnonsmallcelllungcanceridentifiedbybioinformaticsassessment AT wangxianhui expressionsignatureprognosisvalueandimmunecharacteristicsofcathepsinfinnonsmallcelllungcanceridentifiedbybioinformaticsassessment AT chengwang expressionsignatureprognosisvalueandimmunecharacteristicsofcathepsinfinnonsmallcelllungcanceridentifiedbybioinformaticsassessment AT wuyi expressionsignatureprognosisvalueandimmunecharacteristicsofcathepsinfinnonsmallcelllungcanceridentifiedbybioinformaticsassessment AT liumin expressionsignatureprognosisvalueandimmunecharacteristicsofcathepsinfinnonsmallcelllungcanceridentifiedbybioinformaticsassessment AT liuruizi expressionsignatureprognosisvalueandimmunecharacteristicsofcathepsinfinnonsmallcelllungcanceridentifiedbybioinformaticsassessment AT zhangshenyi expressionsignatureprognosisvalueandimmunecharacteristicsofcathepsinfinnonsmallcelllungcanceridentifiedbybioinformaticsassessment AT xiahong expressionsignatureprognosisvalueandimmunecharacteristicsofcathepsinfinnonsmallcelllungcanceridentifiedbybioinformaticsassessment AT liuhao expressionsignatureprognosisvalueandimmunecharacteristicsofcathepsinfinnonsmallcelllungcanceridentifiedbybioinformaticsassessment AT taixuejiao expressionsignatureprognosisvalueandimmunecharacteristicsofcathepsinfinnonsmallcelllungcanceridentifiedbybioinformaticsassessment AT zhaohuzi expressionsignatureprognosisvalueandimmunecharacteristicsofcathepsinfinnonsmallcelllungcanceridentifiedbybioinformaticsassessment AT lixihua expressionsignatureprognosisvalueandimmunecharacteristicsofcathepsinfinnonsmallcelllungcanceridentifiedbybioinformaticsassessment AT jifuyun expressionsignatureprognosisvalueandimmunecharacteristicsofcathepsinfinnonsmallcelllungcanceridentifiedbybioinformaticsassessment |